Abstract
Background Human immunodeficiency virus (HIV) infection is a public health concern globally. The numbers of people living with HIV worldwide in 2018 was estimated at 37.9 million; from those, 1.7 million are children. Globally, 62% of the 37.9 million people were receiving Antiretroviral treatment (ART); 53% had achieved viral suppression. This study aimed to assess the incidence and predictors of Antiretroviral treatment failure among children in Kolfe Keranyo sub-city, Addis Ababa, Ethiopia.
Methods An institution-based retrospective cohort study was conducted among 250 children who were enrolled to first-line Antiretroviral treatment from January 2013 to May 2020 in Kolfe Keranyo sub-city. Data was collected by using data extraction checklist and data were extracted by reviewing children’s medical chart and electronic database. Kaplan–Meier method was used to estimate the probability of treatment failure. During bivariable analysis variables with p-value < 0.25 were taken for multivariable Cox regression analysis to assess predictors of treatment failure. Statistically significant association was declared at p-value < 0.05 with 95% confidence interval.
Result The overall treatment failure rate within the follow-up period was 17.2%. This study also found that the overall incidence density rate was 3.45% (95% CI: 2.57-4.67) per 1000 person-month observation. Infant prophylaxis for PMTCT (AHR: 3.59, 95% CI: 1.65-7,82), drug substitution (AHR: 0.18, 95% CI: 0.09-0.37), AZT/3TC/NVP based regimen (AHR: 2.27, 95% CI: 1.14-4.25), and more than 3 episodes of poor ART adherence (AHR: 2.27, 95% CI: 1.17-4.38) were found to be predictors of treatment failure among children.
Conclusion High proportion of treatment failure was found among children on first-line ART in Kolfe Keranyo sub-city, Addis Ababa. Infant prophylaxis for PMTCT, drug substitution, initial regimen, and poor ART adherence were found to be predictors of first-line ART treatment failure. Close follow-up of children on medication adherence and effective trainings to health care professionals need to be considered.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The authors have not received any finical support from any institution/government hence, the operation of the research is solely financed by the handling fee received from the authors.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical clearance was obtained from the Institution Review Board (IRB) of Addis Ababa Public Health Research and Emergency Management Directorate.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Not Applicable
Footnotes
danielssa25{at}gmail.com
Data Availability
All relevant data are within the manuscript and its Supporting Information files.
Abbreviations
- AIDS
- Acquired Immune Deficiency Syndrome
- ART
- Antiretroviral Treatment
- AZT
- Zidovudine
- DTG
- Dolutegravir
- HAART
- Highly Active Antiretroviral Therapy
- HIV
- Human Immunodeficiency Virus
- IRB
- Institution Review Board
- LPV/r
- Lopinavir / Ritonavir
- NNRTI
- Non-Nucleotide Reverse Transcriptase Inhibitor
- NRTI
- Nucleotide Reverses Transcriptase Inhibitor
- NVP
- Nevirapine
- OI
- Opportunistic Infection
- PI
- Protease Inhibiter
- PMTCT
- Prevention of Mother to Child Transmission
- SPSS
- Statistical Package for Social Sciences
- TB
- Tuberculosis
- VL
- Viral Load
- WHO
- World Health Organization
- 3TC
- Lamivudine
